Empowering engineered phages with CRISPR to modify microbiome for better medicine
Engineering phages for precision delivery of DNA payloads to target bacteria
Innovating DNA payloads by combining CRISPR & synthetic biology science
Controlling traits of target bacteria by customizing its genetic signature
TBX201 is designed to prevent severe diarrhea caused by Irinotecan chemotherapy in cancer patients by oral treatment to target and silence microbiome GUS enzyme (cause of diarrhea), to reduce hospitalizations & improve outcomes and quality of life
TBX301 is designed to remediate Immune Checkpoint Inhibitors (ICI)-associated colitis by oral treatment to locally secrete anti-inflammatory IL-10 in the gut and obviate confounding systemic immunosuppression of ICI efficacy to improve outcomes
The microbiome field phenomenal scientific findings link it to almost every aspect of human health, with a major influence on drug activity.
The translation of these findings into meaningful therapeutics is hampered by the transient nature of most current microbiome products under development.
Trobix Bio addresses this challenge by leveraging its TBX platform to develop precision medicine therapeutics with a lasting and continuous effect.
Our dedicated founders, scientific team and investors are committed to develop life saving therapeutics